Researchers Find Possible Treatment for Suppressed Immunity from Spine Injuries

News provided by

Cincinnati Children's Hospital Medical Center

Apr 18, 2016, 11:00 ET

CINCINNATI, April 18, 2016 /PRNewswire-USNewswire/ -- Scientists report in Nature Neuroscience they have identified an underlying cause of dangerous immune suppression in people with high level spinal cord injuries and they propose a possible treatment.

This microscopic image shows the development of abnormal nervous circuity in the spinal tissues of mouse models with high thoracic spinal injury. The aberrant circuitry causes responses that extend beyond thoracic spinal segments. In this image, fluoresced developing interneurons glow almost like clusters of stars in the night sky. As the circuitry expands, it activated by an interaction with the spleen. This helps trigger a dangerous anti-inflammatory and immune suppressive reflex. Researchers report their results April 18 in the journal Nature Neuroscience.Image credit: Cincinnati Children's

In the journal's April 18 online edition, researchers at Cincinnati Children's Hospital Medical Center and Wexner Medical Center at The Ohio State University write that spinal cord injuries higher than thoracic level 5 (T5) cause autonomic nervous system circuitry to develop a highly adaptable state of plasticity. The autonomic nervous system controls bodily functions that are not consciously directed – like breathing, heartbeat, digestion and immune function.

As the body rushes to react to spinal cord damage, new but abnormal nervous system circuitry starts to form, according to the authors. They show that in mouse models of spinal cord injury, this aberrant nervous system circuitry causes responses that extend beyond thoracic spinal segments, which in uninjured mice would normally feed nerves to secondary lymphoid tissues that help generate immune cells. Because of this, abnormal spinal interneurons are activated by the bladder and/or bowel. This results in formation of an exaggerated network of neural circuitry that activates an anti-inflammatory and immune suppressive reflex.

"Infection, a consequence of immune suppression, is the leading cause of death for people with spinal cord injuries," said Yutaka Yoshida, PhD, co-lead author and a scientist in the Division of Developmental Biology at Cincinnati Children's. "Patients and mouse models of spinal injury also are subject to autonomic dysreflexia, a potentially fatal clinical syndrome marked by episodes of high blood pressure."

People with high-level spinal cord injury develop what is known as spinal cord injury-induced immune suppression syndrome (SCI-IDS). In the study, mouse models of high spinal cord injury have atrophied spleens (a secondary organ that produces white blood cells) and show signs of leukopenia (low white blood cell count).

Co-lead author Phillip Popovich, PhD, professor of Neuroscience and director of the Center for Brain and at Ohio State, said that "this abnormal spinal cord circuitry likely causes chronic immune suppression and increases the chance that people with spinal cord injuries will suffer from complications caused by common infections, such as pneumonia."

In an effort to develop a possible treatment to stop immune suppression syndrome, the researchers tested chemogenetic agents in their laboratory mouse models. Chemogenetics involves manipulating receptors that are on the surface of cells and either activate or silence these cells. The use of chemogenetics creates the ability to exert very selective pharmacologic control over a variety of cell-signaling processes.

In the instance of mouse high spinal cord injury models, the researchers used chemogenetics to silence signaling transmissions from newly forming interneurons that trigger the immune suppression reflex. Because the newly forming nerves had specific genetic signatures, the scientists were able to control these neurons using a precisely targeted chemogenetic silencer (hM4Di-DREADD).

Chemogenetic silencing reversed the immune suppressive reflex in spinal injured mice. Atrophy in the animals' spleens was reversed and white blood cell counts increased, the researchers report.

The researchers continue to test and refine the use of chemogenetic silencing to treat SCI-IDS. They caution that the experimental treatment method remains years away from testing in people with spinal cord injury.

Also collaborating on the study was first author Masaki Ueno, a member of Yoshida's lab at Cincinnati Children's and also the Japan Science and Technology Agency

Funding support for the study came in part from: the National Institute of Neurological Disorders and Stroke (NS083942, NS093002); the Ray W. Poppleton Endowment; PRESTO; the JSPS Postdoctoral Fellowships for Research Abroad and the KANAE Foundation for the Promotion of Medical Science.

About Cincinnati Children's
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S.News and World Report's 2015 Best Children's Hospitals. It is also ranked in the top 10 for all 10 pediatric specialties, including a #1 ranking in pulmonology and #2 in cancer and in nephrology. Cincinnati Children's, a non-profit organization, is one of the top three recipients of pediatric research grants from the National Institutes of Health, and a research and teaching affiliate of the University of Cincinnati's College of Medicine. The medical center is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at www.cincinnatichildrens.org. Connect on the Cincinnati Children's blog, via Facebook and on Twitter.

Photo - http://photos.prnewswire.com/prnh/20160418/356338

SOURCE Cincinnati Children's Hospital Medical Center